Retrospective evaluation of cases diagnosed with central puberty precocious reaching final height

Retrospective evaluation of cases diagnosed with central puberty precocious reaching final height Introduction and Purpose: The aim of this study was to determine the final height achieved by our patients who were treated with GnRHa and whose treatment had ended, to investigate the effect of treatment on body weight and body mass index, and to identify factors related to final height. Materials and Methods: Patients who were diagnosed with CPP, treated with GnRHa, and whose treatment ended between 01.01.2011 and 01.12.2022 at our hospital were included in the study. Data on age at presentation, bone age, onset of symptoms, body weight (BW), BW standard deviation score (SDS), height, height SDS, BMI, BMI SDS, target height, target height SDS, pubertal stages during physical examination, laboratory results (basal LH, FSH, and E2), age at menarche, pelvic ultrasound findings, pituitary and brain MRI reports, age at the start of treatment, and anthropometric and laboratory findings at the end of treatment were recorded from the medical records of the cases included in the study. Results: The mean age at presentation of the 67 female patients treated with GnRHa for CPP was 7.5±0.60 years (min-max: 7.05-7.65). When evaluated according to the SDS values of the patients' BMI at presentation, it was shown that 3 (5%) patients were obese and 13 (19%) were overweight. The BMI SDS at presentation was 0.13±1.13, while the BMI SDS value examined at the end of treatment was found to be 0.04±1.21, and the difference between them was not significant (p:0.47). The mean age at menarche was 11.57±0.78 years. Menarche was found to occur 20.3±10 months after the end of GnRHa treatment. When cranial imaging results were evaluated, no underlying cause was found in 62 (92.5%) cases, while organic pathology was detected in 5 (7.5%) cases. The cases with organic pathology in our study were between 6-8 years of age. In our study, it was determined that 24 (35.8%) of the 67 patients who received GnRHa treatment exceeded their target height, 39 (58.2%) reached their target height, and only 4 (6%) patients remained below their target height. Multiple linear regression analysis was used to evaluate the factors affecting delta height SDS. It was determined that target height SDS had a positive effect on delta height SDS, while the KY/TY ratio had a negative effect. Conclusion: Our study concluded that GnRHa treatment had no negative effect on BMI SDS. Good height SDS and PAH at presentation were associated with a greater likelihood of exceeding target height. Factors affecting delta height SDS were identified using multiple linear regression analysis. Target height SDS had a positive effect on delta height SDS, while the KY/TY ratio had a negative effect. Keywords: Central Precocious Puberty, Final Height, Gonadotropin Releasing Hormone Analog Treatment